(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 27 May 2004 (27.05.2004)

(10) International Publication Number WO 2004/043340 A3

(51) International Patent Classification7:

A61K 48/00

(21) International Application Number:

PCT/US2003/021954

(22) International Filing Date:

16 July 2003 (16.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/396,482

16 July 2002 (16.07.2002) US

- (71) Applicant (for all designated States except US): UNI-VERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 335 George Street, P.O. Box

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report

2688, New Brunswick, NJ 08903 (US).

720 Inventor; and (75) Inventor; Applicant (for US only): WIEDER, Robert (US/US); 330 South Chestnut Street, Westfield, NJ 07090 (US).

74) Agents: MALLON, Veronica et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

75) Abstract: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their cradication through use of standard chemotherapy or radiation therapy. Besi fibroblast growth factor (PGF-2), a marmary differentiated for abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin c951. Most of the major constituent of the bone marrow wireonenvironment, stay alive and growth-arrested for many weeks. Using function of another major constituent of the bone marrow wireonenvironment, stay alive and growth-arrested for many weeks. Using function of actions in the contribution of α5β1-fibronectin integration of the time limit for amending the claims and to be republished in the event of receipt of amendments

88 Date of publication of the international search report:

88 Date of publication of the international search report:

88 Date of publication of the international search report:

88 Date of publication of the international search report:

88 Date of publication of the international search report:

98 Actions and to be republished in the event of receipt of amendments

99 Actions and to be republished in the event of receipt of amendments

90 Actions and to be republished in the event of receipt of amendments

90 Actions and to be republished in the event of receipt of amendments

90 Actions and to be republished in the claim and to be republished in the event of receipt antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy.



al application No. Inte INTERNATIONAL SEARCH REPORT PCT/US03/21954 CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 48/00 514/44 US CL According to International Patent Classification (IPC) or to both national classification and IPC FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/44 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category * 1-53 A,B US 2004/0072775 A1 (SOBEL et. Al.)15 March 2004. Further documents are listed in the continuation of Box C. See patent family annex. later document published after the international filing date or Special categories of cited documents: priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the art which is not considered to be of particular relevance document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive "R" earlier application or patent published on or after the international filing step when the document is taken alone document of particular relevance; the claimed invention cannot be document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document referring to an oral disclosure, use, exhibition or other means document member of the same patent family document published prior to the international filing date but later than the Date of mailing of the international search report Date of the actual completion of the international search Authorized officer Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Alana M. Harris, Ph.D. Commissioner for Patents

Telephone No. (703)308-4/96

Form PCT/ISA/210 (second sheet) (July 1998)

Facsimile No. (703) 305-3230

P.O. Box 1450 Alexandria, Virginia 22313-1450